Delving into the Latest Updates on Citric Acid/Magnesium Oxide/Sodium Picosulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PSMC, Picolight, Sodium Picosulfate Hydrate/Magnesium Oxide/Anhydrous Citric Acid

+ [8]

Target-

Mechanism-

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

Colonic DiseasesIntestinal preparation

Inactive Indication-

Originator Organization

Ferring BV

Active Organization

Ferring Pharmaceuticals, Inc.

Nippon Chemiphar Co., Ltd.

Inactive Organization

Ferring Pharmaceuticals A/S

Drug Highest PhaseApproved

First Approval Date

US (16 Jul 2012),

Intestinal preparation

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H17NNa2O9S2

InChIKeyPUKNPYFKPBSERR-UHFFFAOYSA-N

CAS Registry1307301-38-7

View All Structures (3)

Colonoscopy Preparation: Comparing Sennoside A+B and PM/Ca
Colonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure.
What is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works by stimulating the bowel to move and reducing the absorption of water, making it easier to pass stools. Research has shown that high doses of sennoside A+B can be effective for bowel preparation.
Sennoside A+B vs. PEG:
Some studies have found that sennoside A+B is more effective than PEG, another laxative, but can cause more abdominal pain. Other studies have found no significant difference in effectiveness between the two.
What is Picosulfate/Magnesium Oxide/Citric Acid (PM/Ca)? PM/Ca is a combination of sodium picosulfate, magnesium oxide, and citric acid. Sodium picosulfate stimulates bowel movements, while magnesium oxide and citric acid help increase water in the bowel, making it easier to pass stools.
PM/Ca vs. PEG:
Research has shown that PM/Ca is as effective as PEG for bowel preparation. Patients using PM/Ca generally tolerate the preparation process better than those using PEG.
Conclusion:
While PEG is the preferred option according to guidelines, its high cost can make it less accessible in some places. In this study, we aim to compare the effectiveness and patient tolerance of Sennoside A+B and PM/Ca since no direct comparison between these two preparations has been made before.

Start Date22 Aug 2024

Sponsor / Collaborator

Hittite University

NCT05726097 / CompletedPhase 3

Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

The study aims to investigate the effect of the optimized bowel preparation and boost regimens on colon capsule endoscopy procedures, specifically on cleanliness and completion rate.

Start Date01 Feb 2023

Sponsor / Collaborator

Region Skåne Holding AB

[+2]

NCT04113382 / RecruitingPhase 1/2

A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years

Bowel preparation for pediatric colonoscopy.

Start Date23 Jun 2022

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

100 Clinical Results associated with Citric Acid/Magnesium Oxide/Sodium Picosulfate

Login to view more data

100 Translational Medicine associated with Citric Acid/Magnesium Oxide/Sodium Picosulfate

Login to view more data

100 Patents (Medical) associated with Citric Acid/Magnesium Oxide/Sodium Picosulfate

Login to view more data

28

Literatures (Medical) associated with Citric Acid/Magnesium Oxide/Sodium Picosulfate

01 Apr 2022·DEN Open

Evaluating patient acceptability and bowel preparation efficacy of sodium picosulfate‐magnesium citrate for colonoscopy

Article

Author: Fujishiro, Mitsuhiro ; Tanaka, Daiki ; Saito, Masashi ; Iwase, Hiroaki ; Nakamura, Sumie ; Nishikura, Miho ; Miyazawa, Kaori ; Shimada, Masaaki ; Urata, Noboru ; Fukuhara, Kiyoko ; Kondo, Takashi ; Kondo, Hisashi ; Hirashima, Noboru ; Unita, Satoshi ; Tsunekawa, Takuya

AbstractObjectiveTo evaluate patient acceptability and bowel preparation efficacy of sodium picosulfate‐magnesium citrate (PICOPREP) for colonoscopy.MethodsA questionnaire survey regarding the patient acceptability of bowel preparation agent PICOPREP was administered to 54 patients, and its efficacy was evaluated using the Ottawa Bowel Preparation Scale (OBPS).ResultsEighteen (33.3%) participants reported that PICOPREP is very easy to drink, 30 (55.5%) easy, four (7.4%) acceptable, one (1.9%) difficult, and one (1.9%) very difficult. The flavor was very good as reported by eight (14.8%) participants, good by 25 (46.3%), neutral by 20 (37.0%), bad by one (1.9%), and very bad by none. The number of patients who requested PICOPREP was 42 (77.7%), indicating its high acceptability. Evaluation of the OBPS score showed that the rectosigmoid colon had significantly better polyethylene glycol (PEG) scores than PICOPREP, but the entire colon did not show a significant difference between PICOPREP and PEG scores (1.09 ± 0.65 vs. 1.17 ± 0.76, p = 0.632 in the right colon; 0.48 ± 0.52 vs. 0.72 ± 0.66, p = 0.079 in the mid colon, 0.93 ± 0.49 vs. 0.63 ± 0.52, p = 0.012 in the rectosigmoid colon, and 3.28 ± 1.70 vs. 3.20 ± 1.90, p = 0.836 in the entire colon).ConclusionPICOPREP is considered as one of the important options due to its good patient acceptability and high efficacy similar to PEG.

01 Jan 2020·International Journal of Preventive Medicine

Effects of probiotic soy milk fermented by lactobacillus plantarum A7 (KC 355240) added with Cuminum Cyminum essential oil on fasting blood glucose levels, serum lipid profile and body weight in diabetic Wistar rats

Article

Author: Ghiasvand, Reza ; Torki-Baghbadorani, Sahar ; Mosharaf, Laleh ; Mirlohi, Maryam ; Babashahi, Mina ; Azadbakht, Leila

BACKGROUNDThere is some separate evidence that probiotic soy milk and Cuminum cyminum (C. cyminum) have positive effects on the prevention and reduction of diabetic complications. While the impact of probiotic soymilk mixed with herbal essential oils has not been investigated so far, the objective of this study is to examine the effects of probiotic soy milk using Lactobacillus plantarum A7 (KC 355240) added with essential oil of C. cyminum on diabetic rats.METHODS50 streptozotocin-nicotinamide (STZ-NA) induced diabetic Wistar rats were divided into five groups: Control group (C group), soy milk group (SM group), probiotic soy milk group (PSM group), soy milk containing essential oil of C. cyminum group (SMC group) and probiotic soy milk containing essential oil of C. cyminum group (PSMC group). The animals consumed these products (1 ml/day) for 30 days. The fasting blood glucose (FBS), the serum lipid levels, and body weight variation were analyzed in 10-day intervals.RESULTSFBS, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) decreased significantly, whereas high-density lipoprotein cholesterol (HDL-C) increased in the PSMC group compared with that of other groups (P < 0.05). This product also led to weight gain (P < 0.05).CONCLUSIONSA mixture of probiotic soy milk and herbal essential oil consumption could impose a positive effect on reducing FBS as well as serum lipid profile in STZ- NA diabetes-induced rat. Also, it results in an increase in their weight gain.

01 Feb 2019·American Journal of GastroenterologyQ1 · MEDICINE

Comparing the Real-World Effectiveness of Competing Colonoscopy Preparations: Results of a Prospective Trial

Q1 · MEDICINE

Article

Author: Pattisapu, Varun ; Ko, Jeffrey ; Bullen, Tia ; Mirakhor, Ebrahim ; Vipani, Aarshi ; Fuller, Garth ; Oh, Sun Jung ; Hsu, Kevin ; Lew, Daniel ; Spiegel, Brennan M R ; Almario, Christopher V ; Gu, Phillip

OBJECTIVES:National societies provide little guidance regarding which colonoscopy bowel preps are best tolerated and most effective; this reflects a lack of comparative effectiveness studies that directly evaluate the available preps in a “real-world” setting. To address this gap, we conducted a prospective, commercially unfunded comparative effectiveness study of currently available bowel preps and measured their impact on bowel cleansing.METHODS:We included patients aged ≥18 years, who presented for an outpatient colonoscopy at a large medical center serving more than 70 academic and community-based endoscopists who are free to prescribe the bowel prep of their choice. The primary outcome was bowel cleansing quality as measured by the Boston Bowel Preparation Scale. We performed regression models with random effects on the outcomes to adjust for confounding.RESULTS:Approximately 4,339 colonoscopies were performed by 75 endoscopists. Magnesium citrate, MiraLAX with Gatorade, MoviPrep, OsmoPrep, Prepopik/Clenpiq, and Suprep all had significantly higher prep tolerability compared with GoLYTELY (all P < 0.05). For bowel cleansing, Suprep (7.28 ± 1.66; P < 0.001), MoviPrep (7.11 ± 1.62; P = 0.004), and MiraLAX with Gatorade (7.09 ± 1.64; P < 0.001) had higher total Boston Bowel Preparation Scale scores compared with GoLYTELY (6.67 ± 1.87); there were no significant differences among the remaining preps. Split-prep dosing was associated with better cleansing; however, men, opioid and tricyclic antidepressent users, and patients with diabetes and cirrhosis had worse cleansing (all P < 0.05).CONCLUSIONS:In this prospective, real-world comparative effectiveness study of available bowel preps, we found that MiraLAX with Gatorade, MoviPrep, and Suprep were prospectively associated with superior tolerability and bowel cleansing.

100 Deals associated with Citric Acid/Magnesium Oxide/Sodium Picosulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A06AB58	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colonic Diseases	JP	Nippon Chemiphar Co., Ltd.	04 Jul 2016
Intestinal preparation	US	Ferring Pharmaceuticals, Inc.	16 Jul 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Diseases	Phase 1	US	Ferring Pharmaceuticals, Inc.	15 Aug 2018
Intestinal preparation	Phase 1	DE	Ferring Pharmaceuticals A/S	01 Nov 2014
Intestinal preparation	Phase 1	NL	Ferring Pharmaceuticals A/S	01 Nov 2014
Intestinal preparation	Phase 1	FR	Ferring Pharmaceuticals A/S	01 Nov 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03198221 (CTgov)	Phase 4	-	14	Golytely (Group A)	tuxgevgabb(vdofhlcpbm) = hvetrbesln qggjhxkjfg (qgcrlezcyv, uxrkorxbhh - xfirxdxdwu) View more	-	04 Mar 2021
				Golytely (Group B)	tuxgevgabb(vdofhlcpbm) = aottcmndot qggjhxkjfg (qgcrlezcyv, wmvgqbemjo - rdjtczosve) View more
NCT01978509 (CTgov)	Not Applicable	-	32	Low volume prep (Prepopik) (Low Volume Prep (Prepopik))	qifcpzjtkc(qgkwfczovs) = ipehnhyxhl ulcnawfxdi (dncpopnvxb, wzuevgtoux - ldlfsaytqe) View more	-	17 Jul 2020
				Moderate volume prep (Moviprep) (Moderate Volume Prep (Moviprep))	qifcpzjtkc(qgkwfczovs) = nmbamfzhiq ulcnawfxdi (dncpopnvxb, noaycssiua - wiumbxqzyr) View more
NCT01928862 (Prepopik PREA, CTgov)	Phase 1/2	-	78	Prepopik® ½ Sachet x 2 (9-12 years) (Prepopik® ½ Sachet x 2 (9-12 Years))	nctmyutyet(xqownufhks) = fslygzxbay hkouvyofpm (xnztngggzp, nvqgrsowep - fgeklhgwhd) View more	-	23 Apr 2018
				Prepopik® 1 Sachet x 2 (9-12 years) (Prepopik® 1 Sachet x 2 (9-12 Years))	nctmyutyet(xqownufhks) = uulmhvxdnq hkouvyofpm (xnztngggzp, ohgmjrdlud - qavyezkxbw) View more
NCT02215954 (CTgov)	Phase 3	Colonic Diseases	637	FE 999169 (Treatment Arm [1]: FE 999169)	apxcsyobzs(emlmuwvvgq) = ofxtosvguh gxqniuiygj (fapkgybuqm, gtxmedvxje - xqyybjuauz) View more	-	17 Jul 2017
				FE 999169 (Treatment Arm [2]: FE 999169)	apxcsyobzs(emlmuwvvgq) = tqqmikjgye gxqniuiygj (fapkgybuqm, gutphnxlcq - kmxlqwchfl) View more
NCT02239692 (Pubmed)	Phase 3	-	204	PICOPREP tailored dosing	hmxlpahwjz(cdookscrqz): odds ratio = 9.18 (95% CI, 4.36 - 19.32)	-	01 Apr 2017
				PICOPREP day-before dosing
NCT02239692 (OPTIMA, CTgov)	Phase 3	Intestinal preparation	204	PICOPREP (PICOPREP Day-before Dosing Schedule)	dlypbphuey(vwubtemssy) = hzhhiwexns rmkranczzs (sawsnkgegl, xzybxquugy - xwseynoqzi) View more	-	23 Jun 2016
				PICOPREP (PICOPREP Tailored Dosing Schedule)	dlypbphuey(vwubtemssy) = feoyzzstqg rmkranczzs (sawsnkgegl, bbzvvubvyt - pbnqmbcrrm) View more
NCT01356407 (CTgov)	Phase 3	-	300	PICOPREP	juxpdxjpvm(hqvpfvzipt) = ydqybzireb dlqcyelblt (yhekrljjmi, widjkzpeqk - auillakcvy) View more	-	28 Jan 2013
NCT01073943 (CTgov)	Phase 3	-	603	PicoPrep (PicoPrep)	ctypxwkuru(wsyrptojnh) = lnvllzwomh fuhfeqwsft (ndzmdaotqi, gyrmrafzit - kuenkxqsea) View more	-	11 Sep 2012
				bisacodyl+HalfLytely (HalfLytely)	ctypxwkuru(wsyrptojnh) = ufcaqdwvze fuhfeqwsft (ndzmdaotqi, vsyanzkeko - rsfvuowogs) View more
NCT01073930 (CTgov)	Phase 3	-	608	PicoPrep (PICOPREP)	jkmcsefarr(qlwusgknxj) = klshlrtakf qrrvstqzwk (qcnktqiqwq, ppkroblflw - pqkspmvxqq) View more	-	11 Sep 2012
				bisacodyl+HalfLytely (HalfLytely)	jkmcsefarr(qlwusgknxj) = nfauxywfmc qrrvstqzwk (qcnktqiqwq, kibzopcnul - cotkxpsscm) View more